Table 1.

Univariate and multivariate analysis on survival.

Adverse prognostic factors	N patients/N total	DMFS univariate analysis P value	DMFS multivariate analysis RR, 95% CI, P value	OS univariate analysis P value	OS multivariate analysis RR, 95% CI, P value
Age ≤50 years	41/115	NS (0.99)	—	NS (0.51)	—
Tumor size T3 or T4	53/115	NS (0.13)	—	NS (0.28)	—
Clinical node N1 or N2	73/115	NS (0.64)	—	NS (0.49)	—
Tumor grade III	55/115	NS (0.76)	—	NS (0.55)	—
HR negative	47/115	NS (0.26)	—	0.01	Not included*
HER2 negative	81/115	NS (0.11)	—	0.04	Not included*
Triple negative phenotype	31/115	0.02	RR = 2.4 [0.9–6]   P = 0.06	0.0003	RR = 5.4 [1.6–18]   P = 0.006
Prechemotherapy ≥1 CTC/7.5 mL	22/95	0.04	RR = 2.4 [0.9–6]   P = 0.06	0.03	RR = 3.0 [1.0–9.5]   P = 0.05
Postchemotherapy ≥1 CTC/7.5 mL	15/85	NS (0.29)	—	NS (0.30)	—
Absence of pCR	93/114	NS (0.27)	—	NS (0.68)	—

DMFS: distant metastasis-free survival. OS: overall survival. 95% CI: 95% confidence interval. HR: hormone receptors. NS: nonsignificant. *HR and HER2 statuses, which are redundant to triple negative phenotype, were not included in multivariate analysis.